Patents Assigned to Elixir Medical Corporation
-
Publication number: 20130230571Abstract: The present disclosure provides a device for intracorporeal use which comprises an implant or a temporary device and at least one source of myolimus or a derivative thereof. The present disclosure also provides a method of inhibiting cell proliferation, inflammation or cytokine production by systemic or local administration of a therapeutically effective amount of myolimus or a derivative thereof. Further included in the present disclosure is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of myolimus or a derivative thereof.Type: ApplicationFiled: October 3, 2011Publication date: September 5, 2013Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak Bhat
-
Publication number: 20130150943Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: June 28, 2012Publication date: June 13, 2013Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Patent number: 8404641Abstract: A method of inhibiting cell migration or treating an inflammatory condition, comprising administering a compound disclosed herein to the subject, is provided. The compound can be administered systemically, locally, or a combination thereof. For example, the compound can be locally delivered from a temporary device or an implant, such as a vascular prosthesis.Type: GrantFiled: December 21, 2011Date of Patent: March 26, 2013Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 8367081Abstract: A method of inhibiting smooth muscle cell proliferation or cytokine production in a subject, comprising administering a compound disclosed herein to the subject, is provided. The compound can be administered systemically, locally, or a combination thereof. For example, the compound can be locally delivered from a temporary device or an implant, such as a vascular prosthesis.Type: GrantFiled: December 21, 2011Date of Patent: February 5, 2013Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 8323760Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: GrantFiled: May 16, 2012Date of Patent: December 4, 2012Assignee: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20120271396Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: July 2, 2012Publication date: October 25, 2012Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20120226345Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20120187606Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: ApplicationFiled: March 29, 2012Publication date: July 26, 2012Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Patent number: 8182890Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: GrantFiled: January 17, 2008Date of Patent: May 22, 2012Assignee: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20120094932Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6 and R8 are each independently a member selected from the group consisting of H, C1-6 alkyl and OH; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites and prodrugs thereof.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20120093891Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6 and R8 are each independently a member selected from the group consisting of H, C1-6 alkyl and OH; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites and prodrugs thereof.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20120071500Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: November 22, 2011Publication date: March 22, 2012Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20120071962Abstract: Stents are provided with scaffold structures which have low exposures when implanted in arteries and other blood vessels and lumens. The cross-sectional dimensions, materials, and patterns are controlled to provide sufficient strength and coverage while maintaining the low exposure.Type: ApplicationFiled: December 10, 2010Publication date: March 22, 2012Applicant: Elixir Medical CorporationInventors: Howard Huang, John Yan, Vinayak Bhat, Motasim Sirhan
-
Patent number: 8088789Abstract: A method of treating an ophthalmic condition or disease by administering a compound disclosed herein is provided. The compound can be administered systemically or locally and in a variety of ways, such as via a temporary device, an implant, an injection or an eye drop. The compound can also be administered with an additional therapeutic agent.Type: GrantFiled: March 11, 2008Date of Patent: January 3, 2012Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20110097364Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6 and R8 are each independently a member selected from the group consisting of H, C1-6 alkyl and OH; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites and prodrugs thereof.Type: ApplicationFiled: December 2, 2010Publication date: April 28, 2011Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 7867988Abstract: A method of inhibiting smooth muscle cell proliferation or cytokine production in a subject, comprising administering a compound disclosed herein to the subject, is provided. The compound can be administered systemically, locally, or a combination thereof. For example, the compound can be locally delivered from a temporary device or an implant, such as a vascular prosthesis.Type: GrantFiled: September 12, 2007Date of Patent: January 11, 2011Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20100086579Abstract: The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof.Type: ApplicationFiled: October 2, 2009Publication date: April 8, 2010Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20090228094Abstract: Luminal prostheses comprise scaffolds having coatings adhered to at least a portion of their outer surfaces. The surfaces are modified to enhance binding of the coatings. For example, the surfaces may be microblasted, laser treated, chemically etched, exposed to plasma, or exposed to a corona discharge, allowing a polymeric coating to adhere to the scaffold more tightly than in the absence of the surface modification. The coatings can be used to deliver therapeutic or other agents dispersed therein.Type: ApplicationFiled: April 20, 2009Publication date: September 10, 2009Applicant: Elixir Medical CorporationInventors: John Yan, Howard Huang, Vinayak D. Bhat
-
Publication number: 20080234309Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: March 11, 2008Publication date: September 25, 2008Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20080177374Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: ApplicationFiled: January 17, 2008Publication date: July 24, 2008Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat